Falk Gastro Info 12/2015

Video

 

Video course abdominal ultrasound

Right liver lobe, 3 levels

 

Author: Prof. Dr. Christoph F. Dietrich, Caritas Krankenhaus Bad Mergentheim.

© 2015 Falk Foundation e.V., Freiburg. All rights reserved.

 

 

Please switch on your loudspeakers!

 

 

Link to Falk Mediacenter:

http://media.falkfoundation.de/index.php?id=121&L=1

 

Link to the video directly:

http://media.drfalkpharma.de/fileadmin/media/06_Liver_Right_liver_lobe_3_levels_ENG.mp4

 

 

Preview images:

 

580 x 325 pixels (with arrow)

http://www.drfalkpharma.com/fileadmin/media/newsletter/Logos/Vorschau_Sono_Clip06_580P.jpg

 

580 x 325 pixels (without arrow)

http://www.drfalkpharma.com/fileadmin/media/newsletter/Logos/Vorschau_Sono_Clip06_580.jpg

 

 

 

 

Latest research in brief:

 

Description field (to be displayed at the end of the structural element):

 

 

Bowel

http://www.drfalkpharma.com/fileadmin/media/logos_falk/abstracts/Falk-Darm.png

 

 

Text:

Böhn L et al, Gastroenterology. 2015;149(6):1399–1407.e2

Dietary approaches for irritable bowel syndrome: A diet low in FODMAP reduces symptoms as well as traditional dietary advice (regular meal pattern, avoidance of fat, insoluble fibers, caffeine, and gas-producing foods).

 

Link:

http://www.drfalkpharma.com/index.php?L=1&id=20376#30591

 

 

Text:

Khanna R et al, Lancet. 2015;386(10006):1825–34

Therapy algorithms for Crohn’s disease: Early combined immunosuppression (antimetabolite plus TNF antagonist) is not superior to conventional therapy in controlling disease activity, but results in reduced rates of disease-related complications including operations and hospital admissions.

 

Link:

http://www.drfalkpharma.com/index.php?L=1&id=20376#c30592

 

 

Text:

Baron JA et al, N Engl J Med. 2015;373(16):1519–30

Prevention of colorectal adenomas: Daily supplementation of vitamin D3 (1000 IU), calcium (1200 mg) or both after removal of adenomas does not reduce the risk of recurrent colorectal adenomas over a period of 3–5 years.

 

Link:

http://www.drfalkpharma.com/index.php?L=1&id=20376#c30593

 

 

 


 

Liver
Biliary Tracts

http://www.drfalkpharma.com/fileadmin/media/logos_falk/abstracts/Falk-Leber.png

 

 

Text:

Roth D et al, Lancet. 2015;386(10003):1537–45

Hepatitis C: In patients with chronic kidney disease stage 4–5 (including patients on hemodialysis) and hepatitis C virus genotype 1, once daily grazoprevir plus elbasvir is well tolerated and highly efficient (sustained virological response rate 99%).

 

Link:

http://www.drfalkpharma.com/index.php?L=1&id=20376#c30594

 

 

Text:

van Meer S et al, J Hepatol. 2015;63(5):1156–63

Hepatocellular carcinoma (HCC): The benefit of surveillance for HCC is controversial. A Dutch study now demonstrated that surveillance for HCC is associated with smaller tumor size and earlier tumor stage at HCC diagnosis, impacts therapeutic strategy and is an independent predictor of survival.

 

Link:

http://www.drfalkpharma.com/index.php?L=1&id=20376#c30595

 

 

Text:

Kirstein MM et al, Hepatology. 2015;62(5):1524–35

Autoimmune hepatitis: Diagnosis at an age < 18 years, histological presence of cirrhosis at diagnosis, and detection of SLA/LP antibodies are main risk factors for a poor short and long-term outcome of autoimmune hepatitis. Positivity for DRB1-04:01, in contrast, is associated with a favorable clinical course.

 

Link:

http://www.drfalkpharma.com/index.php?L=1&id=20376#c30596

 

 

 

 


 

Oesophagus

Stomach

Duodenum

http://www.drfalkpharma.com/fileadmin/media/logos_falk/abstracts/Falk-Magen.png

 

 

Text:

Moawad FJ et al, Gut. 2015;64(12):1874–80

Barrett’s esophagus length is established at the time of initial endoscopy and does not change over time.

 

Link:

http://www.drfalkpharma.com/index.php?L=1&id=20376#c30597

 

 

Text:

Choung RS et al, Clin Gastroenterol Hepatol. 2015;13(11):1937–43

Symptoms indicative of functional gastrointestinal disorders and seropositive celiac disease are relatively common in a U.S. white community. However, testing for celiac disease in patients with irritable bowel syndrome may not result in improved detection of patients with celiac disease.

 

Link:

http://www.drfalkpharma.com/index.php?L=1&id=20376#c30598

 

 

Text:

Zeng M et al, Lancet. 2015;386(10002):1457–64

Vaccination against Helicobacter pylori: An oral recombinant vaccine was effective and safe in a randomized placebo-controlled phase III trial of previously uninfected children and resulted in immunogenic responses in 71,8% of study participants.

 

Link:

http://www.drfalkpharma.com/index.php?L=1&id=20376#c30599

 

 

 

 

Pancreas

http://www.drfalkpharma.com/fileadmin/media/logos_falk/abstracts/Falk-Pankreas.png

 

 

Text:

da Costa DW et al, Lancet. 2015;386(10000):1261–8

Biliary pancreatitis: Compared with interval cholecystectomy, same-admission cholecystectomy reduces the rate of recurrent biliary complications with a very low risk of surgery-associated complications.

 

Link:

http://www.drfalkpharma.com/index.php?L=1&id=20376#c30600

 

 

Falk Symposia

 

 

Workshop

Communications and System Relevance in Liver Damage and Regeneration

 

Bild:

http://www.drfalkpharma.com/fileadmin/media/newsletter/falk_workshop.gif

 

Text:

January 21 – 22, 2016, Düsseldorf, Germany

Building 23.01, Hörsaal 3D, Heinrich-Heine University, Universitätsstr. 1, 40225 Düsseldorf, Germany

 

Link1:

http://www.drfalkpharma.com/fileadmin/media/Falk_Veranstaltungen/Falk_Symposien_und_Workshops/WS_Duesseldorf_2016_Preliminary_Program.pdf

 

Link2:

http://www.drfalkpharma.com/fileadmin/media/Falk_Veranstaltungen/Falk_Symposien_und_Workshops/WS_Duesseldorf_2016_Registration.pdf

 

Link für Online-Anmeldung:

http://events.falkfoundation.com/index.php?id=42&L=1

 

 

 

 

Symposium 201

Gut-Liver Interactions: From IBD to NASH

 

Bild:

http://www.drfalkpharma.com/fileadmin/media/newsletter/symposium.gif

 

Text:

March 11 – 12, 2016, Innsbruck, Austria

Congress Innsbruck, Rennweg 3, 6020 Innsbruck, Austria

 

Link1:

http://www.drfalkpharma.com/fileadmin/media/Falk_Veranstaltungen/Falk_Symposien_und_Workshops/FS201_Innsbruck_2016_Preliminary_Program.pdf

 

Link2:

http://www.drfalkpharma.com/fileadmin/media/Falk_Veranstaltungen/Falk_Symposien_und_Workshops/FS201_Innsbruck_2016_Registration.pdf

 

Link für Online-Anmeldung:

http://events.falkfoundation.com/index.php?id=205&L=1

 

 

 

 

Symposium 202

Evolving Therapies in Clinical Practice in IBD

 

Bild:

http://www.drfalkpharma.com/fileadmin/media/newsletter/symposium.gif

 

Text:

April 29 – 30, 2016, Prague, Czech Republic

Hilton Prague, Pobrezni 1, 18600 Prague 08, Czech Republic

 

Link1:

http://www.drfalkpharma.com/fileadmin/media/Falk_Veranstaltungen/Falk_Symposien_und_Workshops/FS202_Prague_2016_Preliminary_Program.pdf

 

Link2:

http://www.drfalkpharma.de/fileadmin/media/Falk_Veranstaltungen/Falk_Symposien_und_Workshops/FS202_Prague_2016_Registration.pdf

 

Link für Online-Anmeldung:

http://events.falkfoundation.com/index.php?id=206&L=1

 

 

 

 

Current Falk literature:

 

Microscopic colitis – Collagenous and lymphocytic colitis

Author: A. Tromm

(50 pages)

Revised edition 2015

BU6e

 

Picture:

http://www.drfalkpharma.com/fileadmin/media/Falk_Broschueren/Diagnostik_und_Therapie/Titelblatt/Bu6e_8-9-15.jpg

 

PDF:

http://www.drfalkpharma.com/fileadmin/media/Falk_Broschueren/Diagnostik_und_Therapie/PDF/Bu6e_8-9-15.pdf

 

 

 

Order by email (Please replace text by your email address):

 

mailto:text?subject=FGI%212%2F2015:%20Ordering%20of%20brochure%20BU6e&body=Please%20send%20the%20brochure%20to%20the%20following%20address:%0A%0A